about
Structural Studies and Protein Engineering of Inositol Phosphate MultikinaseA sugar phosphatase regulates the methylerythritol phosphate (MEP) pathway in malaria parasitesMuddled mechanisms: recent progress towards antimalarial target identificationGlobal proteomic analysis of prenylated proteins in Plasmodium falciparum using an alkyne-modified isoprenoid analogueThe triphenylethylenes, a novel class of antifungals.Malaria parasites produce volatile mosquito attractantsResistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr).A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose TransportersPlasmodium IspD (2-C-Methyl-D-erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target.Molecular Mechanism of Action of Antimalarial Benzoisothiazolones: Species-Selective Inhibitors of the Plasmodium spp. MEP Pathway enzyme, IspDIsoprenoid biosynthesis in Plasmodium falciparum.Isoprenoid metabolism in apicomplexan parasites.MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis.Infectious complications of pediatric cochlear implants are highly influenced by otitis media.Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin.The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir.Cap-domain closure enables diverse substrate recognition by the C2-type haloacid dehalogenase-like sugar phosphatase Plasmodium falciparum HAD1Calcineurin is required for virulence of Cryptococcus neoformans.A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling.Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene.Breathprinting Reveals Malaria-Associated Biomarkers and Mosquito Attractants.Natural History of Plasmodium odocoilei Malaria Infection in Farmed White-Tailed Deer.Characterization of the MFalpha pheromone of the human fungal pathogen cryptococcus neoformans.Tackling resistance: emerging antimalarials and new parasite targets in the era of eliminationMalaria in ChildrenThe MEP pathway and the development of inhibitors as potential anti-infective agentsSuppression of Drug Resistance Reveals a Genetic Mechanism of Metabolic Plasticity in Malaria ParasitesSweet Talk: Regulating Glucose Metabolism in ToxoplasmaMEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against MalariaThe Effect of Acrylamide and Other Sulfhydryl Alkylators on the Ability of Dynein and Kinesin to Translocate Microtubules in VitroComparison of breath sampling methods: a post hoc analysis from observational cohort studiesPediatric tropical medicine: The neglected diseases of childrenIdentification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineeringInsights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13Breath Collection from Children for Disease Biomarker DiscoveryHaloacid Dehalogenase Proteins: Novel Mediators of Metabolic Plasticity in Plasmodium falciparumPotent, specific MEPicides for treatment of zoonotic staphylococci
P50
Q27671552-54344E4B-54E5-4631-8C8A-B1B9CE83B10BQ27684806-99DD083C-603F-47F3-9321-570FA75E0361Q28066421-5A14DAA8-F7CE-4468-A895-F8A3B8D3B399Q28817814-08FEDA8A-257A-4BA5-A1FF-E9EE27DEF571Q33569534-ED3C1604-1F0A-423F-BBBC-8356CD6ABF7CQ35677491-39B0C3EB-9CFD-4B2E-B4F7-20A0B75D60D7Q35678194-7BE80725-6FBF-425B-BB37-5C1E36F36F8DQ36162383-503B2FFE-0A70-4A40-8AEA-B4D2E756482EQ36467783-1D6FCAD3-586B-4B04-9D70-6DF7BA99D189Q37421946-8AC1B6A4-009F-4548-9D4D-C2F679E7CE46Q38248821-86D8F506-298F-4355-85ED-39331CFF8770Q38429627-638667F5-A210-455D-AE83-F161EA6F7AAEQ38615212-2E785D05-BC2D-45E0-A769-26C1D28277DAQ38797409-CE095F51-F8AF-484B-8CCD-AC17EB377E73Q38839163-7B8636B5-91AB-476A-AA33-0527521C74F6Q41066112-9BEE0671-2F3A-4C00-B182-45683563ABD3Q41828032-0291E945-775F-4273-8A53-27D6022A2705Q42617596-2E9E878F-D27C-49F1-B591-CDAE59577A0EQ42722311-089547A7-824F-4B51-B957-68233FF86FB9Q42925343-CF5848B6-0C39-49EE-B3B2-B823AD3FD350Q50132786-2D227FC7-AFD8-42C1-96FF-6FBD842303BCQ52579716-62689ED0-53BA-40CE-A3AB-9C3EAB35A253Q53900199-E6ED0CA5-E3E8-4430-AE08-8FDC8BF1A834Q56350408-FCBC7643-86E0-4C99-9480-783BE33BC443Q56395219-A807AE45-9AAD-4175-9B83-EE14A0D70E2BQ56994497-2621875F-4820-4AF3-90BF-A29228BF86D2Q59132650-A31CB939-4879-4111-A06F-FEBF248B0400Q60544327-1A37BBC6-1951-46BC-B27C-A53CF27CFD94Q61951059-E48D71E0-971A-43C3-8586-7A65516F32DFQ61951088-CDE2A711-CD7E-4F00-ABCA-A30F90444749Q62487335-CAFF9D48-321B-4036-8070-5CFB796682FBQ64060579-4AEB72AE-30D0-4336-AB77-6F229CE6FA60Q64060897-542780D1-5A36-4EDA-97B6-6E8A6D4DD35BQ92078712-A3583B9C-9CAB-4A70-8B95-03D3C5B4F36CQ92096032-2FDCD8E1-5BF5-4A54-9AE5-4C24D53D10D4Q92794278-1C9D8BA3-55FC-46C9-9360-328F68D1FA15Q96121585-4D8CE33E-B84C-4243-8068-76FF2647CD19
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Audrey R Odom
@es
Audrey R. Odom
@en
Audrey R. Odom
@nl
اودري آر. أودوم
@ar
type
label
Audrey R Odom
@es
Audrey R. Odom
@en
Audrey R. Odom
@nl
اودري آر. أودوم
@ar
altLabel
Audrey John
@en
Audrey Odom John
@en
Audrey Odom
@en
Audrey R. Odom John
@en
prefLabel
Audrey R Odom
@es
Audrey R. Odom
@en
Audrey R. Odom
@nl
اودري آر. أودوم
@ar
P106
P1153
7003997524
P21
P31
P496
0000-0001-8395-8537
P569
2000-01-01T00:00:00Z